Virendra Rambiritch

University Rd
Westville, ZN, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Novel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial.

Novel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial.

Journal: JMIR research protocols

Published: November 03, 2022

Optimal dosing of gliclazide-A model-based approach.

Optimal dosing of gliclazide-A model-based approach.

Journal: Basic & clinical pharmacology & toxicology

Published: October 04, 2022

Real-world evidence and product development: Opportunities, challenges and risk mitigation.

Real-world evidence and product development: Opportunities, challenges and risk mitigation.

Journal: Wiener klinische Wochenschrift

Published: December 08, 2020

Management of adult patients with type 1 diabetes mellitus in Africa: A post-hoc cohort analysis of 12 African countries participating in the International Diabetes Management Practices Study (Wave 7).

Management of adult patients with type 1 diabetes mellitus in Africa: A post-hoc cohort analysis of 12 African countries participating in the International Diabetes Management Practices Study (Wave 7).

Journal: Medicine

Published: June 23, 2020

Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.

Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.

Journal: Advances in therapy

Published: September 23, 2019

PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.

PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.

Journal: Endocrine, metabolic & immune disorders drug targets

Published: September 14, 2019

Patient blood management: A solution for South Africa.

Patient blood management: A solution for South Africa.

Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde

Published: June 28, 2019

Non-referral of potential organ donors in South Africa: insights, challenges and ethical dilemmas.

Non-referral of potential organ donors in South Africa: insights, challenges and ethical dilemmas.

Journal: The Pan African medical journal

Published: January 04, 2018

Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects.

Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects.

Journal: Clinical pharmacology : advances and applications

Published: October 08, 2016

Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects.

Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects.

Journal: Clinical pharmacology : advances and applications

Published: July 30, 2016

Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study.

Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study.

Journal: JMIR research protocols

Published: August 26, 2015

Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study.

Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study.

Journal: Clinical pharmacology : advances and applications

Published: April 18, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026